Lung Cancer Awareness Month: Potential new standard in NSCLC, immunotherapy timing matters
Click Here to Manage Email Alerts
Lung Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors of the disease.
It also promotes the need for screening among eligible populations, as well as the importance of research underway to identify more effective treatments.
In conjunction with Lung Cancer Awareness Month, Healio presents 12 important updates in lung cancer treatment that may be relevant to your practice.
1. Single-fraction stereotactic body radiation therapy may be an effective treatment for individuals with central lung cancer, according to data presented at American Society for Radiation Oncology Annual Meeting. Read more.
2. Data from a phase 3 trial designed to compare pralsetinib (Gavreto, Rigel Pharmaceuticals) with standard therapy for certain patients with advanced lung cancer revealed a risk for severe — and potentially fatal — infections with the drug. Read more.
3. Clinical and genetic risk factors can help identify individuals at risk for immune checkpoint inhibitor-induced diabetes. Read more.
4. Adjuvant durvalumab (Imfinzi, AstraZeneca) significantly improved PFS and OS compared with placebo among patients with limited-stage small cell lung cancer, according to data presented at ESMO Congress. Read more.
5. Concurrent administration of chemoradiation and immunotherapy did not improve survival for patients with limited-stage small cell lung cancer. The disparate results from this study and a prior randomized phase 3 trial suggest the timing of immunotherapy greatly influences its benefit. Read more.
6. The FDA approved osimertinib (Tagrisso, AstraZeneca) for treatment of certain patients with locally advanced or unresectable non-small cell lung cancer. Read more.
7. Acceptance and utilization of lung cancer biomarker testing has increased in the past 6 years, but key barriers persist. Read more.
8. Immunotherapy before and after surgery significantly improved EFS compared with neoadjuvant immunotherapy only for patients with resectable NSCLC. Read more.
9. Ivonescimab (SMT112, Summit Therapeutics) significantly improved PFS compared with pembrolizumab (Keytruda, Merck) as first-line treatment of PD-L1-positive advanced NSCLC. The results highlight ivonescimab’s potential as “a new standard of care,” according to investigators. Read more.
10. The introduction of immunotherapy to treatment paradigms has improved survival for patients with metastatic NSCLC. Read more.
11. The FDA approved amivantamab-vmjw (Rybrevant, Janssen) in combination with standard chemotherapy for the treatment of certain adults with NSCLC. Read more.
12. Neoadjuvant atezolizumab prior to chemoradiation therapy exhibited promising activity for patients with unresectable stage III NSCLC. Read more.
Collapse
Healio Coverage
Click Here to Manage Email Alerts